Chiron Real Estate Q3 net loss widens, Core FFO falls

By Reuters News


Overview

  • US healthcare REIT's Q3 net loss widened year-over-year

  • Q3 included $2 mln in severance and transition costs tied to shift to seniors housing


Outlook

  • Company sees strong investor interest in medical office assets and plans to expand seniors housing

  • Chiron continues to pursue sale of outpatient medical portfolio, expects to redeploy proceeds

  • Company expects newly opened seniors housing assets to stabilize at yields above 7% by 2028-2029


Result Drivers

  • OUTPATIENT MEDICAL PORTFOLIO - Co said it is actively pursuing the sale of its outpatient medical portfolio, with market conditions for medical office assets described as strong

  • SENIORS HOUSING EXPANSION - Co expanded its seniors housing platform and acquired new properties, aiming to redeploy capital for future growth

  • SEVERANCE AND TRANSITION COSTS - Q3 results included $2 mln in severance and transition expenses related to the company's shift toward seniors housing


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Rental Revenue

$33.52 mln

Q3 Net Loss

$5.74 mln

Q3 Core FFO

$10.86 mln

Q3 FFO

$7.28 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the specialized reits peer group is "buy"

  • Wall Street's median 12-month price target for Chiron Real Estate Inc is $43.00, about 41.5% above its November 3 closing price of $30.38


Reuters Recommended Reads

  • Nov 2 - Senior housing REIT Janus Living's Q3 revenue jumps 78%, FFO up 46%

  • Nov 2 - Diversified Healthcare Trust Q3 net loss narrows amid occupancy growth

  • Nov 2 - Sabra Health Care REIT Q3 revenue rises year-over-year


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.